Now, we go deep into a serious issue that has received a lot of attention and press – data integrity. I’d venture to guess that billions of market capital has been lost because of this one issue. The crazy part is this – it’s not even close to being a new issue. As you’ll see, the data integrity story began at least 15 years ago. Here’s Barbara:

This article uses the example of data integrity enforcement actions over the past ten-plus years and identifies the missed opportunities where firms failed to learn from publicly available information. Many have suffered expensive consequences, both financial, and in reputation within the industry. Table 1 provides a selected list of enforcement actions based on shortcomings in the broad category of data integrity.

May webinar - recording

As early as 2000, a warning letter issued to Schein Pharmaceuticals cited lack of control over computerized laboratory systems[1] including lack of password control and broad ranging staff authority to change data. Another event was a 15-page form FDA-483 issued to Able Laboratories in New Jersey in 2005. Warning letters citing deficiencies in the broad area of data integrity were issued to Actavis Totowa LLC and Sandoz sites, both in the US followed in 2007 and 2008 respectively. Three warning letters were issued to two Ranbaxy sites in 2006 and 2008. The Ranbaxy inspections and warning letters were eventually followed by import alerts, a consent decree agreement, fines and loss of generic product exclusivity. In addition, Wockhardt Ltd. and Changzhou SPL Company received warning letters in 2006 and 2008 respectively, citing concerns about the authenticity and integrity of data. Even discounting the warning letter to Schein Pharmaceuticals in 2000, these early signals, from 2005-2009, were publicly available from regulators as well as being covered in the popular press and trade publications. Firms missed multiple opportunities to learn from the mistakes of others, immediately evaluate, and initiate remediation if necessary. Table 1 shows that enforcement actions based on data integrity have continued into 2015 with similar inspection observations and warning letter deficiencies.

Finally, FDASIA became law in July 2012 and introduced a revised definition of adulteration to include products manufactured by any firm that “…delays, denies, or limits an inspection…” FDA used this justification several times in issuance of warning letters, the first two of which are identified in Table 1. If firms tracked new legislation, particularly in the draft versions, they would have been informed about the expanded definition of “adulteration”. Publication of a draft and then final guidance clarified and expanded on the revised definition of adulteration.

Table 1. Selected Enforcement Actions for Data Integrity Problems

FYCompanyAdditional Enforcement Actions or Comment
2000Schein PharmaceuticalsWarning letter to Schein Pharmaceuticals cites inadequate control over laboratory computer systems including password control and authority to change data.
2005Able Laboratories, Cranbury NJThe 15 page form 483 was among the early forms 483 addressing the broad category of data integrity.   Resulted in withdrawal of ~ 50 ANDAs and the firm is no longer in business.
2007Actavis Totowa LLC, NJElectronic data files not checked for accuracy; data discrepancies between electronic data and data documented in laboratory notebooks.
2008Sandoz, site in NCAnalysts may modify, overwrite or delete data; no audit trails or history of revisions in analytical data
2006Ranbaxy, Paonta SahibImport alerts were issued for four Ranbaxy sites, two dated 9/10/2009 and two dated 9/13/2009.  Ranbaxy entered into a consent decree agreement with the courts in January 2012. Ranbaxy agreed to pay a $500,000 fine in May 2013. Additional Ranbaxy site at Toansa, India was added to the consent decree agreement in January 2014See the FDA timetable of enforcement actions and associated documentation including some forms 483.
2008Ranbaxy, Paonta Sahib
2008Ranbaxy, Dewas
2009Ranbaxy Ohm Laboratories in Gloversville NY
2008Changzhou SPL CompanyImport alert dated September 10, 2009
2011Cetero Research(untitled letter)This firm, located in the US conducted BA/BE studies in support of NDAs and ANDAs. It is no longer in business. Forms 483 here. FDA sent a letter to the firms that contracted with Cetero Research for BA/BE studies requesting specific information to establish validity of the BA/BE information in the drug applications.
2006Wockhardt LtdAnother warning letter form 2006 that mentions issues in the data integrity area. The 2013 warning letter was the second warning letter that cited the new FDASIA power to determine products adulterated if they are manufactured at a site that “delays, denies or limits” an inspection. The FY 2014 letter addresses two sites owned by the company. Import alerts issued for two sites in India on May 22, 2013 and November 26, 2013. The 6-page form 483 to Morton Grove Pharmaceuticals identifies similar practices to those found to be objectionable at the sites in India
2013Wockhardt Limited
2014Wockhardt Limited
2014Morton Grove Pharmaceuticals (US site owned by Wockhardt)
2012Fercy Personal Care Products LtdImport alert issued May 10, 2012
2013Fresenius Kabi Oncology LtdThis represents the first warning letter to cite the FDASIA definition of adulteration to include products made in a facility that “delays, denies or limits” an inspection.
2014Apotex Pharmachem India Pvt Ltd.Import alerts issued April 1, 2014 and April 22, 2014
2015Apotex Research Private Ltd.
2014Tripfarma S.p.AThis site in Italy has data integrity type of issues identified in this recent warning letter.

The collection of enforcement actions in Table 1 and agency documents span more than ten years and covers both GMP and GCP. Firms located in the US, EU, India and China have been cited for data integrity problems. If firms read and internalized the actions at Schein Pharmaceuticals, Able Laboratories in Cranbury NJ, Actavis Totowa LLC in NJ and Sandoz in NC, followed the Ranbaxy series of actions, there is no reason to claim surprise in this enforcement area in 2016. Note that the earliest publicly available signals of the problem occurred during inspections of sites in the US. Enforcement for lack of data integrity is not limited to actions taken by FDA. The public section of the Eudra GMDP database was expanded in 2014 to include reports of non-compliance, many of which address the area of data integrity identified during inspections conducted by the European authorities. Also, MHRA first published a series of Q&A on this topic in January 2015 that was revised in March 2015. Anyone interested in data integrity should read, and re-read this.

It does not take a complicated financial formula to see that there are financial consequences for these compliance actions. For example, Able Laboratories ceased doing business, Cetero Research is no longer a business entity, Ranbaxy is in the process of being acquired by another pharmaceutical company in India, and Wockhardt Ltd’s sales are severely diminished in the US[2].

CONCLUSION:

Data are publicly available to inform companies about changes in GMP laws, regulations, guidance, and inspection focus and enforcement trends. The example of data integrity is not meant to be the only topic for which this is true, but it is one where firms have suffered financial consequences resulting from enforcement actions. A GMP Regulatory Intelligence program should provide analysis and connect the dots among different types of information and multiple enforcement actions over time. New and important boilerplate language in a warning letter should be identified and communicated. Warning letters that identify new types of deficiencies, for example the absence of audit trails, are important to evaluate. Likewise, warning letters that identify seemingly stringent requirements that can be linked to similar requirements in consent decree agreements should be highlighted. An effective comprehensive GMP Regulatory Intelligence program meets the requirements in ICHQ10 and serves as a component of a corporate knowledge management system. Finally, the financial return is substantial if the program provides actionable knowledge to prevent a warning letter, import alert, seizure or the more serious consent decree agreement. Companies should consider that this applies across the GXP continuum, and is not limited to GMP activities alone.

(Footnotes)

    1. [1] The warning letter is not available on the current FDA web site and must be requested under FOI. Following is the specific deficiency.
    2. Failure to maintain the integrity and adequacy of the laboratory’s computer systems used by the Quality Control Unit in the analysis and processing of test data. For example:

a) There was a lack of a secure system to prevent unauthorized entry in restricted data systems. Data edit authorization rights were available to all unauthorized users, not only the system administrator.

b) The microbiology departments original reports on sterility test failures of Penicillin G Potassium for injection, lots 9804024 and 9811016 due to environmental mold, which were sent via electronic mail to the Quality Assurance Management, differed significantly from the versions included in the Quality Assurance Management’s official reports.

c) The network (b) (4) module design limitations, which can only support up to four chromatographic data acquisition systems, had up to five chromatographic systems connected. There was no validation showing this configuration to be acceptable.

d) System testing was not conducted to insure that each system as configured could handle high sampling rates. Validation of the systems did not include critical system tests such as volume, stress, performance, boundary and compatibility.[2] See article in FiercePharma from 11/3/2014.

May webinar - recording

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Systems

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.